Effectiveness and tolerability of THC:CBD oromucosal spray as add-on measure in patients with severe chronic pain: analysis of 12-week open-label real-world data provided by the German Pain e-Registry

References

• Bonica JJ. The Management of Pain. Philadelphia: Lea & Febiger; 1953.
   Google Scholar
• Treede RD. Entstehung der Schmerzchronifizierung [Development of pain chronification] In: Baron R, Koppert W, Strumpf M, Willweber-Strumpf A, editors. Praktische Schmerztherapie. Heidelberg: Springer; 2011:3–13. German.
   Google Scholar
• Merskey H, Bogduk N. Classification of Chronic Pain. 2nd ed. Seattle: IASP Press; 1994.
   Google Scholar
• Breivik H, Collett B, Ventafridda V, Cohen R, Gallacher D. Survey of chronic pain in Europe: prevalence, impact on daily life, and treatment. Eur J Pain. 2006;10:287. doi:10.1016/j.ejpain.2005.06.00916095934
   PubMed Web of Science ®Google Scholar
• Goldberg DS, Summer JM. Pain as a global public health priority. BMC Public Health. 2011;11:770. doi:10.1186/1471-2458-11-77021978149
   PubMed Web of Science ®Google Scholar
• Gureje O, von Korff M, Kola L, et al. The relation between multiple pains and mental disorders: results from the World Mental Health Surveys. Pain. 2008;135:82–91. doi:10.1016/j.pain.2007.05.00517570586
   PubMed Web of Science ®Google Scholar
• Koleva D. Pain in primary care: an Italian survey. Eur J Public Health. 2005;15:475–479. doi:10.1093/eurpub/cki03316150816
   PubMed Web of Science ®Google Scholar
• Mäntyselkä P, Kumpusalo E, Ahonen R, et al. Pain as a reason to visit the doctor: a study in Finnish primary health care. Pain. 2001;89:175–180.11166473
   PubMed Web of Science ®Google Scholar
• Leger JM. Diagnosis of chronic neuropathy. J Neurol. 1999;246:156–161.10323310
   PubMed Web of Science ®Google Scholar
• Freynhagen R, Baron R. The evaluation of neuropathic components in low back pain. Curr Pain Headache Rep. 2009;13:185–190.19457278
   PubMed Web of Science ®Google Scholar
• Beith ID, Kemp A, Kenyon J, Prout M, Chestnut TJ. Identifying neuropathic back and leg pain: a cross-sectional study. Pain. 2011;152:1511–1516. doi:10.1016/j.pain.2011.02.03321396774
   PubMed Web of Science ®Google Scholar
• Smart KM, Blake C, Staines A, Doody C. Self-reported pain severity, quality of life, disability, anxiety and depression in patients classified with ‘nociceptive’, ‘peripheral neuropathic’ and ‘central sensitisation’ pain. The discriminant validity of mechanisms-based classifications of low back (±leg) pain. Man Ther. 2012;17:119–125. doi:10.1016/j.math.2011.10.00222074733
   PubMed Web of Science ®Google Scholar
• Cherkin DC, Sherman KJ, Balderson BH, et al. Comparison of complementary and alternative medicine with conventional mind-body therapies for chronic back pain: protocol for the Mind-body Approaches to Pain (MAP) randomized controlled trial. Trials. 2014;15:211–215. doi:10.1186/1745-6215-15-21124906419
   PubMed Web of Science ®Google Scholar
• Lee C, Crawford C, Buckenmaier C, Schoomaker E, Delgado R, York A. Active, self-care complementary and integrative medicine therapies for the management of chronic pain symptoms: A rapid evidence assessment of the literature. J Altern Complement Med. 2014;20:A137–A138. doi:10.1089/acm.2014.5368.abstract
   Google Scholar
• Breen J. Transitions in the concept of chronic pain. ANS Adv Nurs Sci. 2002;24:48–59.12699276
   PubMed Web of Science ®Google Scholar
• Dworkin RH, O’Connor AB, Backonja M, et al. Pharmacologic management of neuropathic pain: evidence based recommendations. Pain. 2007;132(3):237–251. doi:10.1016/j.pain.2007.08.03317920770
   PubMed Web of Science ®Google Scholar
• Moulin DE, Clark AJ, Gilron I, et al. Pharmacological management of chronic neuropathic pain consensus statement and guidelines from the Canadian pain society. Pain Res Manage. 2007;12(1):13–21. doi:10.1155/2007/730785
   PubMed Web of Science ®Google Scholar
• Jensen TS, Madsen CS, Finnerup NB. Pharmacology and treatment of neuropathic pains. Curr Opin Neurol. 2009;22(5):467–474. doi:10.1097/WCO.0b013e3283311e1319741531
   PubMed Web of Science ®Google Scholar
• O’Connor AB, Dworkin RH. Treatment of neuropathic pain: an overview of recent guidelines. Am J Med. 2009;122(10 Suppl):S22–S32. doi:10.1016/j.amjmed.2009.04.007
   PubMed Web of Science ®Google Scholar
• Attal N, Cruccu G, Baron R, et al. EFNS guidelines on the pharmacological treatment of neuropathic pain: 2010 revision. Eur J Neurol. 2010;17(9):1113–e88. doi:10.1111/j.1468-1331.2010.02999.x20402746
   PubMed Web of Science ®Google Scholar
• Dworkin RH, O’Connor AB, Audette J, et al. Recommendations for the pharmacological management of neuropathic pain: an overview and literature update. Mayo Clin Proc. 2010;85(3 Suppl):S3–S14. doi:10.4065/mcp.2009.0649
   PubMed Web of Science ®Google Scholar
• Finnerup NB, Attal N, Haroutounian S, et al. Pharmacotherapy for neuropathic pain in adults: systematic review, meta-analysis and updated NeuPSIG recommendations. Lancet Neurol. 2015;14(2):162–173. doi:10.1016/S1474-4422(14)70251-025575710
   PubMed Web of Science ®Google Scholar
• Global Burden of Disease Study 2013 Collaborators. Global, regional, and national incidence, prevalence, and years lived with disability for 301 acute and chronic diseases and injuries in 188 countries, 1990–2013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet. 2015;386:743–800. doi:10.1016/S0140-6736(15)60692-426063472
   PubMed Web of Science ®Google Scholar
• Classification of Chronic Pain. Descriptions of chronic pain syndromes and definitions of pain terms. Prepared by the International Association for the Study of pain, subcommittee on taxonomy. Pain. 1986;3(Suppl):S1–226.3461421
   PubMedGoogle Scholar
• Gesetz zur Änderung betäubungsmittelrechtlicher und anderer Vorschriften. Bundesgesetzblatt 2017 11 1 Available from: https://www.bgbl.de/xaver/bgbl/start.xav?start=%2F%2F*%5B%40attr_id%3D%27bgbl117s0403.pdf%27%5D#__bgbl__%2F%2F*%5B%40attr_id%3D%27bgbl117s0403.pdf%27%5D__1537108060099. Accessed 916, 2018.
   Google Scholar
• Häuser W, Finnerup NB, Moore RA. Systematic reviews with meta-analysis on cannabis-based medicines for chronic pain: a methodological and political minefield. Pain. 2018;159:1906–1907. doi:10.1097/j.pain.000000000000129529847473
   PubMed Web of Science ®Google Scholar
• Allan GM, Finley CR, Ton J, et al. Systematic review of systematic reviews for medical cannabinoids: pain, nausea and vomiting, spasticity, and harms. Can Fam Physician. 2018;64:e78–94.29449262
   PubMed Web of Science ®Google Scholar
• Stockings E, Campbell G, Hall WD, et al. Cannabis and cannabinoids for the treatment of people with chronic noncancer pain conditions: a systematic review and meta-analysis of controlled and observational studies. Pain. 2018;159:1932–1954. doi:10.1097/j.pain.000000000000129329847469
   PubMed Web of Science ®Google Scholar
• Häuser W, Fitzcharles MA, Radbruch L, Petzke F. Cannabis in der Schmerz- und Palliativmedizin [Cannabinoids in pain management and palliative medicine]. Dtsch Arztebl Int. 2017;114(38):627–634. German. doi:10.3238/arztebl.2017.062729017688
   PubMed Web of Science ®Google Scholar
• Friemel CM, von Keller R, Kabisch J. Cannabis: potential und Risiken. Eine wissenschaftliche Analyse (CaPRis). Available from: https://www.bundesgesundheitsministerium.de/fileadmin/Dateien/5_Publikationen/Drogen_und_Sucht/Berichte/Kurzbericht/171127_Kurzbericht_CaPRis.pdf. Accessed 916, 2018.
   Google Scholar
• National Academies of Sciences, Engineering, and Medicine. The Health Effects of Cannabis and Cannabinoids: The Current State of Evidence and Recommendations for Research. Washington (DC): National Academies Press; 2017.
   Google Scholar
• Romero-Sandoval EA, Kolano AL, Alvarado-Vazquez PA. Cannabis and cannabinoids for chronic pain. Curr Rheumatol Rep. 2017;11:67. doi:10.1007/s11926-017-0693-1
   Web of Science ®Google Scholar
• Sativex EMA label. 2015
   Google Scholar
• Deutsche Schmerzgesellschaft. Deutscher Schmerzfragebogen [German pain questionnaire]. Available from: http://www.dgss.org/deutscher-schmerzfragebogen. Accessed 916, 2018.
   Google Scholar
• Deutsche Schmerzgesellschaft. Handbuch zum Deutschen Schmerzfragebogen [Manual for the German pain questionnaire]. Available from: http://www.dgss.org/fileadmin/pdf/12_DSF_Manual_2012.2.pdf. Accessed 916, 2018.
   Google Scholar
• Karniol IG, Carlini EA. Pharmacological interaction between cannabidiol and delta 9-tetrahydrocannabinol. Psychopharmacologia. 1973;33(1):53–70.4358666
   PubMed Web of Science ®Google Scholar
• Fernandes M, Schabarek A, Coper H, Hill R. Modification of delta9-THC-actions by cannabinol and cannabidiol in the rat. Psychopharmacologia. 1974;38(4):329–338.4473791
   PubMed Web of Science ®Google Scholar
• Karniol IG, Shirakawa I, Kasinski N, Pfeferman A, Carlini EA. Cannabidiol interferes with the effects of delta 9-tetrahydrocannabinol in man. Eur J Pharmacol. 1974;28(1):172–177.4609777
   PubMed Web of Science ®Google Scholar
• Zuardi AW, Shirakawa I, Finkelfarb E, Karniol IG. Action of cannabidiol on the anxiety and other effects produced by delta 9-THC in normal subjects. Psychopharmacology. 1982;76(3):245–250.6285406
   PubMed Web of Science ®Google Scholar
• Hollister LE, Gillespie H. Interactions in man of delta-9-tetrahydrocannabinol. II. Cannabinol and cannabidiol. Clin Pharmacol Ther. 1975;18(1):80–83.1097148
   PubMed Web of Science ®Google Scholar
• Morgan CJ, Gardener C, Schafer G, et al. Sub-chronic impact of cannabinoids in street cannabis on cognition, psychotic-like symptoms and psychological wellbeing. Psychol Med. 2012;42(2):391–400. doi:10.1017/S003329171100132221798112
   PubMed Web of Science ®Google Scholar
• Wright MJ Jr, Vandewater SA, Taffe MA. Cannabidiol attenuates deficits of visuospatial associative memory induced by D(9) tetrahydrocannabinol. Br J Pharmacol. 2013;170(7):1365–1373. doi:10.1111/bph.1219923550724
   PubMed Web of Science ®Google Scholar
• Hindocha C, Freeman TP, Schafer G, et al. Acute effects of delta-9-tetrahydrocannabinol, cannabidiol and their combination on facial emotion recognition: a randomised, double-blind, placebo-controlled study in cannabis users. Eur Neuropsychopharmacol. 2015;25(3):325–334. doi:10.1016/j.euroneuro.2014.11.01425534187
   PubMed Web of Science ®Google Scholar
• Cappelleri JC, Bienen EJ, Koduru V, Sadosky A. Measurement properties of painDETECT by average pain severity. Clinicoecon Outcomes Res. 2014;6:497–504. doi:10.2147/CEOR.S6899725395867
   PubMedGoogle Scholar
• Baron R, Maier C, Attal N, et al. Peripheral neuropathic pain: a mechanism-related organizing principle based on sensory profiles. Pain. 2017;158(2):261–272. doi:10.1097/j.pain.000000000000075327893485
   PubMed Web of Science ®Google Scholar
• Tait RC, Chibnall JT, Krause S. The pain disability index: psychometric properties. Pain. 1990;40:171–182.2308763
   PubMed Web of Science ®Google Scholar
• Casser HR, Hüppe M, Kohlmann T, et al. Deutscher Schmerzfragebogen (DSF) und standardisierte Dokumentation mit KEDOQ-Schmerz [German pain questionnaire and standardised documentation with the KEDOQ-Schmerz]. Der Schmerz. 2012;26(2):168–175. German. doi:10.1007/s00482-011-1142-022527646
   PubMed Web of Science ®Google Scholar
• Hayes CJ, Bhandari NR, Kathe N, Payakachat N. Reliability and validity of the medical outcomes study short form-12 version 2 (SF-12v2) in adults with non-cancer pain. Healthcare (Basel). 2017;5(2):E22. doi:10.3390/healthcare502002228445438
   PubMedGoogle Scholar
• Lovibond PF, Lovibond SH. The structure of negative emotional states: comparison of the Depression Anxiety Stress Scales (DASS) with the beck depression and anxiety inventories. Behav Res Ther. 1995;33(3):335–343.7726811
   PubMed Web of Science ®Google Scholar
• Basler HD. Marburger Fragebogen zum habituellen Wohlbefinden - Untersuchung an Patienten mit chonischem Schmerz [The Marburg questionnaire on habitual health findings - A study on patients with chronic pain]. Schmerz. 1999;13(6):385–391. German. doi:10.1007/s00482990004712799914
   PubMed Web of Science ®Google Scholar
• Guy W. ECDEU Assessment Manual for Psychopharmacology. revised US Department of Health, Education, and Welfare publication (ADM) Rockville (MD): National Institute of Mental Health; 1976.
   Google Scholar
• The Committee for Medicinal Products for Human Use (CHMP). Guideline on Clinical Investigation of Medicinal Products Intended for the Treatment of Neuropathic Pain London. London, United Kingdom: European Medicines Agency; 2004 CHMP/EWP/252/03.
   Google Scholar
• Colloca L, Ludman T, Bouhassira D, et al. Neuropathic pain. Nat Rev Dis Primers. 2017;3:17002. doi:10.1038/nrdp.2017.228205574
   PubMed Web of Science ®Google Scholar
• Attal N, Cruccua G, Haanpää M, et al. EFNS guidelines on pharmacological treatment of neuropathic pain. Eur J Neurol. 2006;13(11):1153–1169. doi:10.1111/j.1468-1331.2006.01511.x17038030
   PubMed Web of Science ®Google Scholar
• Turk DC, Audette J, Levy RM, Mackey SC, Stanos S. Assessment and treatment of psychosocial comorbidities in patients with neuropathic pain. Mayo Clin Proc. 2010;85:S42–S50. doi:10.4065/mcp.2009.064820194148
   PubMed Web of Science ®Google Scholar
• Cruccu G, Truini A. A review of neuropathic pain: from guidelines to clinical practice. Pain Ther. 2017;6(Suppl):S35–S42. doi:10.1007/s40122-017-0087-0
   Web of Science ®Google Scholar
• Portenoy RK, Ganae-Motan ED, Allende S, et al. Nabiximols for opioid-treated cancer patients with poorly-controlled chronic pain: a randomized, placebo-controlled, graded-dose trial. J Pain. 2012;13(5):438–449. doi:10.1016/j.jpain.2012.01.00322483680
   PubMed Web of Science ®Google Scholar
• Langford RM, Mares J, Novotna A, et al. A double-blind, randomized, placebo-controlled, parallel-group study of THC/CBD oromucosal spray in combination with the existing treatment regimen, in the relief of central neuropathic pain in patients with multiple sclerosis. J Neurol. 2013;260(4):984–997. doi:10.1007/s00415-012-6739-423180178
   PubMed Web of Science ®Google Scholar
• Lynch ME, Cesar-Rittenberg P, Hohmann AG. A double-blind, placebo-controlled, crossover pilot trial with extension using an oral mucosal cannabinoid extract for treatment of chemotherapy-induced neuropathic pain. J Pain Symptom Manage. 2014;47(1):166–173. doi:10.1016/j.jpainsymman.2013.02.01823742737
   PubMed Web of Science ®Google Scholar
• Serpell M, Ratcliffe S, Hovorka J, et al. A double-blind, randomized, placebo-controlled, parallel group study of THC/CBD spray in peripheral neuropathic pain treatment. Eur J Pain. 2014;18(7):999–1012. doi:10.1002/j.1532-2149.2013.00445.x24420962
   PubMed Web of Science ®Google Scholar
• Baron R, Binder A, Wasner G. Neuropathic pain: diagnosis, pathophysiological mechanisms, and treatment. Lancet Neurol. 2010;9:807–819. doi:10.1016/S1474-4422(10)70143-520650402
   PubMed Web of Science ®Google Scholar
• Maier C, Baron R, Toelle TR, et al. Quantitative sensory testing in the German Research Network on Neuropathic Pain (DFNS): somatosensory abnormalities in 1236 patients with different neuropathic pain syndromes. Pain. 2010;150:439–450. doi:10.1016/j.pain.2010.05.00220627413
   PubMed Web of Science ®Google Scholar
• Campbell JN, Meyer RA. Mechanisms of neuropathic pain. Neuron. 2006;52:77–92. doi:10.1016/j.neuron.2006.09.02117015228
   PubMed Web of Science ®Google Scholar
• Max MB. Towards physiologically based treatment of patients with neuropathic pain. Pain. 1990;42:131–137.1701044
   PubMed Web of Science ®Google Scholar
• Woolf CJ, Bennett GJ, Doherty M, et al. Towards a mechanism-based classification of pain? Pain. 1998;77:227–229.9808347
   PubMed Web of Science ®Google Scholar
• Hansson P. Difficulties in stratifying neuropathic pain by mechanisms. Eur J Pain. 2003;7:353–357. doi:10.1016/S1090-3801(03)00051-X12821406
   PubMed Web of Science ®Google Scholar
• Jensen TS, Baron R. Translation of symptoms and signs into mechanisms in neuropathic pain. Pain. 2003;102:1–8.12620591
   PubMed Web of Science ®Google Scholar
• Lauer MS, Topol EJ. Clinical trials - multiple treatments, multiple end points, and multiple lessons. JAMA. 2003;289:2575–2577. doi:10.1001/jama.289.19.257512759328
   PubMed Web of Science ®Google Scholar
• Committee for Proprietary Medicinal Products (CPMP). International conference on harmonization. Guideline E9, statistical principles for clinical trials. Available from: http://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Efficacy/E9/Step4/E9_Guideline.pdf. Assessed 916, 2018.
   Google Scholar
• Committee for Proprietary Medicinal Products (CPMP). Points to consider on multiplicity issues in clinical trials. http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2009/09/WC500003640.pdf. Accessed 9 16, 2018.
   Google Scholar
• Freemantle N, Calvert M, Wood J, Eastaugh J, Griffin C. Composite outcomes in randomized trials. Greater precision but with greater uncertainty? JAMA. 2003;289:2554–2559. doi:10.1001/jama.289.19.255412759327
   PubMed Web of Science ®Google Scholar
• Montori VM, Permanyer-Miralda G, et al. Validity of composite endpoints in clinical trials. Br Med J. 2005;330:594–596. doi:10.1136/bmj.330.7491.59415761002
   PubMed Web of Science ®Google Scholar
• Collin C, Davies P, Mutiboko IK, Ratcliffe S. Sativex spasticity in MS Study Group. Randomized controlled trial of cannabis-based medicine in spasticity caused by multiple sclerosis. Eur J Neurol. 2007;14(3):290–296. doi:10.1111/j.1468-1331.2006.01639.x17355549
   PubMed Web of Science ®Google Scholar
• Collin C, Ehler E, Waberzinek G, et al. A double-blind, randomized, placebo controlled, parallel-group study of Sativex, in subjects with symptoms of spasticity due to multiple sclerosis. Neurol Res. 2010;32(5):451–459. doi:10.1179/016164109X1259051868566020307378
   PubMed Web of Science ®Google Scholar
• Novotna A, Mares J, Ratcliffe S, et al. A randomized, double-blind, placebo-controlled, parallel-group, enriched-design study of nabiximols (Sativex®), as add-on therapy, in subjects with refractory spasticity caused by multiple sclerosis. Eur J Neurol. 2011;18(9):1122–1131. doi:10.1111/j.1468-1331.2010.03328.x21362108
   PubMed Web of Science ®Google Scholar
• Vachová M, Novotná A, Mareš J, et al. A multicentre, double-blind, randomised, parallel-group, placebo-controlled study of effect of long-term Sativex® treatment on cognition and mood of patients with spasticity due to multiple sclerosis. J Mult Scler. 2014;1(2):10000122.
   Google Scholar
• Koehler J, Feneberg W, Meier M, Pöllmann W. Clinical experience with THC:CBD oromucosal spray in patients with multiple sclerosis-related spasticity. Int J Neurosci. 2014;124(9):652–656. doi:10.3109/00207454.2013.87746024392812
   PubMed Web of Science ®Google Scholar
• Oreja-Guevara C, Casanova B, Ordás CM, Silván CV, Asensio D, Massana M. Observational Safety Study of THC: CBD oromucosal spray (Sativex) in multiple sclerosis patients with spasticity. Clin Exp Pharmacol. 2015;5(5):184.
   Google Scholar
• Flachenecker P, Henze T, Zettl UK. Long-term effectiveness and safety of nabiximols (tetrahydrocannabinol/cannabidiol oromucosal spray) in clinical practice. Eur Neurol. 2014;72(1–2):95–102. doi:10.1159/00036028524943098
   PubMed Web of Science ®Google Scholar
• Flachenecker P, Henze T, Zettl UK. Nabiximols (THC/CBD oromucosal spray, Sativex®) in clinical practice – results of a multicenter, non-interventional study (MOVE2) in patients with multiple sclerosis spasticity. Eur Neurol. 2014;71(5–6):271–279. doi:10.1159/00035742724525548
   PubMed Web of Science ®Google Scholar
• Etges T, Karolia K, Grint T, et al. An observational postmarketing safety registry of patients in the UK, Germany, and Switzerland who have been prescribed Sativex® (THC:CBD, Nabiximols) oromucosal spray. Ther Clin Risk Manag. 2016;12:1667–1675. doi:10.2147/TCRM.S11501427956834
   PubMed Web of Science ®Google Scholar
• Wade DT, Makela P, Robson P, House H, Bateman C. Do cannabis-based medicinal extracts have general or specific effects on symptoms in multiple sclerosis? A double-blind, randomized, placebo-controlled study on 160 patients. Mult Scler. 2004;10(4):434–441. doi:10.1191/1352458504ms1082oa15327042
   PubMed Web of Science ®Google Scholar
• Serpell MG, Notcutt W, Collin C. Sativex long-term use: an open-label trial in patients with spasticity due to multiple sclerosis. J Neurol. 2013;260(1):285–295. doi:10.1007/s00415-012-6634-z22878432
   PubMed Web of Science ®Google Scholar
• Patti F, Messina S, Solaro C, et al. Efficacy and safety of cannabinoid oromucosal spray for multiple sclerosis spasticity. J Neurol Neurosurg Psychiatry. 2016;87(9):944–951. doi:10.1136/jnnp-2015-31259127160523
   PubMed Web of Science ®Google Scholar
• Robinson CB, Fritch M, Hullett L, et al. Development of a protocol to prevent opioid-induced constipation in patients with cancer: A research utilization project. Clin J Oncol Nurs. 2000;4(2):79–84.11107380
   PubMedGoogle Scholar
• Nagel B, Pfingsten M, Lindena G, Nilges P. Handbuch Deutscher Schmerzfragebogen [Handbook German pain questionnaire]. Available from: http://www.dgss.org/fileadmin/pdf/12_DSF_Manual_2012.2.pdf. Accessed 916, 2018 German.
   Google Scholar
• Bundesvereinigung K. Qualitätssicherungsvereinbarung zur schmerztherapeutischen Versorgung chronisch schmerzkranker Patienten gem. § 135 Abs. 2 SGB V. (Qualitätssicherungsvereinbarung Schmerztherapie). Available from: https://www.kbv.de/media/sp/Schmerztherapie.pdf. Accessed 916, 2018 German.
   Google Scholar